CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Oxidative Stress and Cardiovascular Risk: Obesity, Diabetes, Smoking, and Pollution: Part 3 of a 3-Part Series ACC Clinical Bulletin Focuses on Cardiac Implications of Coronavirus (COVID-19) CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Hemodynamic Response to Nitroprusside in Patients With Low-Gradient Severe Aortic Stenosis and Preserved Ejection Fraction Inflammation: A New Target For CAD Treatment and Prevention Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation

Editorial2018 Jan 6;391(10115):3-4.

JOURNAL:Lancet. Article Link

Last nail in the coffin for PCI in stable angina?

Brown DL, Redberg RF. Keywords: comment; stable angina; PCI

ABSTRACT


Interventional cardiology began in Switzerland in 1977, when Andreas Gruentzig performed the first successful percutaneous transluminal coronary angioplasty (PTCA) on a 38-year-old man with angina and a focal proximal stenosis of the left anterior descending coronary artery. Despite numerous subsequent randomised trials and meta-analyses of these trials, which have shown no reduction in death or myocardial infarction,1 the use of percutaneous coronary intervention (PCI) has grown exponentially. Some of this growth was driven by data from clinical trials suggesting that PCI was more effective in relieving angina than medical therapy alone.